<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126646</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000438672</org_study_id>
    <secondary_id>NCI-05-C-0171</secondary_id>
    <secondary_id>NCI-P6620</secondary_id>
    <secondary_id>NCI-5336</secondary_id>
    <nct_id>NCT00126646</nct_id>
    <nct_alias>NCT00114751</nct_alias>
  </id_info>
  <brief_title>BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase I Study of BL22, A Recombinant Immunotoxin for Chronic Lymphocytic Leukemia and CD22+ Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: BL22 immunotoxin can find tumor cells and kill them without harming normal cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of BL22 immunotoxin in&#xD;
      treating patients with refractory B-cell chronic lymphocytic leukemia, prolymphocytic&#xD;
      leukemia, or non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of recombinant BL22 immunotoxin in patients with&#xD;
           CD22-positive refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia,&#xD;
           or indolent non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Determine the safety and efficacy of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the immunogenicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the effect of this drug on various components of the circulating cellular&#xD;
           immune system in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, dose-escalation study. Patients are stratified according to&#xD;
      disease type (chronic lymphocytic leukemia vs non-Hodgkin's lymphoma).&#xD;
&#xD;
      Patients receive recombinant BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5.&#xD;
      Treatment repeats ≥ every 27 days for up to 6 courses in the absence of neutralizing&#xD;
      antibodies to BL22 or PE38, disease progression, or unacceptable toxicity. Patients achieving&#xD;
      a complete response (CR) receive 2 additional courses beyond CR. Patients who relapse from a&#xD;
      CR lasting ≥ 6 months may receive additional courses.&#xD;
&#xD;
      Cohorts of 3-6 patients per stratum receive escalating doses of recombinant BL22 immunotoxin&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24 patients (12 per stratum) will be accrued for this study&#xD;
      within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL22 immunotoxin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antibody-drug conjugate therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunotoxin therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of B-cell leukemia or lymphoma of 1 of the following types:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
                    -  Failed standard chemotherapy&#xD;
&#xD;
               -  Prolymphocytic leukemia&#xD;
&#xD;
                    -  Failed standard chemotherapy&#xD;
&#xD;
               -  Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma&#xD;
&#xD;
                    -  Stage III or IV disease&#xD;
&#xD;
                    -  Failed ≥ 1 prior doxorubicin- or fludarabine-containing standard therapy&#xD;
&#xD;
          -  CD22-positive disease, as evidenced by 1 of the following:&#xD;
&#xD;
               -  More than 15% malignant cells react with anti-CD22 by immunohistochemistry&#xD;
&#xD;
               -  More than 30% malignant cells are CD22-positive by fluorescence-activated cell&#xD;
                  sorting analysis&#xD;
&#xD;
               -  More than 400 CD22 sites per malignant cell (average) by radiolabeled anti-CD22&#xD;
                  binding&#xD;
&#xD;
          -  Treatment is medically indicated, as evidenced by any of the following:&#xD;
&#xD;
               -  Progressive disease-related symptoms&#xD;
&#xD;
               -  Progressive cytopenias due to marrow involvement&#xD;
&#xD;
               -  Progressive or painful splenomegaly or adenopathy&#xD;
&#xD;
               -  Rapidly increasing lymphocytosis&#xD;
&#xD;
               -  Autoimmune hemolytic anemia or thrombocytopenia&#xD;
&#xD;
               -  Increased frequency of infections&#xD;
&#xD;
          -  No neutralizing anti-toxin or anti-mouse immunoglobulin G (IgG) antibodies to BL22 or&#xD;
             PE38&#xD;
&#xD;
               -  No serum neutralization of &gt; 75% of the activity of 1 μg/mL of BL22&#xD;
&#xD;
          -  No CNS disease requiring treatment&#xD;
&#xD;
          -  No hairy cell leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count &gt; 40,000/mm^3 NOTE: *Patients with leukemia are eligible regardless of&#xD;
             absolute neutrophil count; Grade III-IV pancytopenia or growth factor dependence&#xD;
             allowed if due to disease&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &lt; 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV1 ≥ 60% of predicted&#xD;
&#xD;
          -  DLCO ≥ 55% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior bone marrow transplantation allowed&#xD;
&#xD;
          -  More than 3 weeks since prior biologic therapy, including interferon, denileukin&#xD;
             diftitox, or LMB-2 immunotoxin&#xD;
&#xD;
          -  More than 3 months since prior monoclonal antibody therapy (e.g., rituximab)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 1 week since prior steriods&#xD;
&#xD;
               -  Less than 5 doses for non-treatment reasons (e.g., allergy prophylaxis)&#xD;
&#xD;
               -  No evidence of disease response&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior whole-body electron beam radiotherapy&#xD;
&#xD;
               -  Radiotherapy within the past 3 weeks allowed provided the volume of bone marrow&#xD;
                  treated is &lt; 10% AND the patient has measurable disease located outside the&#xD;
                  radiation port&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 weeks since prior retinoids&#xD;
&#xD;
          -  More than 3 weeks since other prior systemic therapy for this malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kreitman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005 Sep 20;23(27):6719-29. Epub 2005 Aug 1.</citation>
    <PMID>16061911</PMID>
  </results_reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>August 2, 2005</study_first_submitted>
  <study_first_submitted_qc>August 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>June 17, 2010</last_update_submitted>
  <last_update_submitted_qc>June 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Kreitman , MD</name_title>
    <organization>NCI</organization>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

